44 results
8-K
EX-99.1
ARVN
Arvinas Inc
6 Dec 23
Regulation FD Disclosure
7:01am
collaboration with Arvinas exemplifies our shared commitment to bringing new therapies to patients with ER+/HER2- breast cancer, who may feel uncertain
S-3ASR
ARVN
Arvinas Inc
7 Nov 23
Automatic shelf registration
5:24pm
appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis.
The distribution of the securities may be effected from … with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase
8-K
EX-99.1
uohaft828grrbf
8 Aug 23
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:03am
8-K
EX-99.1
q8vq6yb9bjhu39yzrt
16 Dec 22
Arvinas Announces Changes to its Board of Directors
9:02am
424B5
73xqdkl9uoi4xzau tz
6 Aug 21
Prospectus supplement for primary offering
4:34pm
8-K
EX-99.1
5qsw1vh 3fhdpxrx8jx
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-10.2
urx31ujuq rkzkcg
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
424B5
weo499s7yr08kvu wvd7
16 Dec 20
Prospectus supplement for primary offering
4:01pm